Wednesday December 12, 2018

The American Cancer Society Recommends Testing For Colon And Rectal Cancer At Age 45

Colon cancer, combined with rectal cancer, is the second leading cause of cancer death in the U.S.

0
//
The group said the initial test does not have to be a colonoscopy.
The American Cancer Society recommends people who are in good health and with a life expectancy of more than 10 years continue regular colorectal cancer screening through the age of 75. Pixabay
Republish
Reprint

The American Cancer Society is recommending people start testing for colon and rectal cancer at age 45, rather than 50 as currently prescribed.

It also recommends people who are in good health and with a life expectancy of more than 10 years continue regular colorectal cancer screening through the age of 75.

“All of these tests are good tests"
“The best test is the test that gets done.”, said the cancer society’s Dr. Rich Wender. Pixabay

The group said the initial test does not have to be a colonoscopy, but instead could be one of several non-invasive tests, such as a home stool test available by prescription.

“All of these tests are good tests, and the choice should be offered to patients,” said the cancer society’s Dr. Rich Wender. “The best test is the test that gets done.”

The change in procedure is based on new information about a marked increase in the incidences of colorectal cancer, particularly rectal cancer, among younger individuals. Experts aren’t sure why there has been a 50 percent increase in cases since 1994.

Read More: According To WHO, Smoking Is A major Cause Of Death And Disease

Most colon cancer occurs in adults 55 and older, and the good news is that rates of cases and deaths have been falling for decades. Colon cancer, combined with rectal cancer, is the second leading cause of cancer death in the U.S.

This year, more than 140,000 Americans are expected to be diagnosed with it, and about 50,000 will die from it. (VOA)

 

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

World’s Smallest Wearable Can Help in Preventing Skin Cancer

It also demonstrated the ability to measure white light exposure for seasonal depression, a mood disorder characterised by depression that occurs at the same time every year

0
cancer
World's smallest device to prevent skin cancer, mood disorder risk. Pixabay

Scientists have developed the world’s smallest wearable, battery-free device that can warn people of overexposure to ultraviolet rays (UV) — a leading factor for developing skin cancer.

Currently, people do not know how much UV light they are actually getting. The rugged and waterproof device interacts wirelessly with the phone and helps maintain an awareness and for skin cancer survivors.

Smaller than an M&M (colourful button-shaped chocolates) and thinner than a credit card, the device can optimise treatment of neonatal jaundice, skin diseases, seasonal affective disorder and reduce risk of sunburns and skin cancer.

Users can glue the device on to their hats, clip it to sunglasses or stick it on their nail and can simultaneously record up to three separate wavelengths of light.

It is always on yet never needs to be recharged.

“There is a critical need for technologies that can accurately measure and promote safe UV exposure at a personalised level in natural environments,” said Steve Xu, from Northwestern University in the US.

Cancer
Cancer Ribbon. Pixabay

“We hope people with information about their UV exposure will develop healthier habits when out in the sun,” said Xu.

There are no switches or interfaces to wear out, and it is completely sealed in a thin layer of transparent plastic, the researchers stated, in the paper published in the journal Science Translational Medicine.

Participants who mounted device on themselves recorded multiple forms of light exposure during outdoor activities, even in the water.

Also Read- First NASA Probe to Return Asteroid Sample Reaches Destination

The findings showed that it monitored therapeutic UV light in clinical phototherapy booths for psoriasis and atopic dermatitis (immune diseases) as well as blue light phototherapy for newborns with jaundice in the neonatal intensive care unit.

It also demonstrated the ability to measure white light exposure for seasonal depression, a mood disorder characterised by depression that occurs at the same time every year. (IANS)